nach oben

European Journal of Drug Metabolism and Pharmacokinetics

Erschienen in:

01.02.2018 | Original Research Article

Effects of Glycyrrhizic Acid on the Pharmacokinetics of Pristimerin in Rats and its Potential Mechanism

verfasst von: Xiufen Zhao, Yan Wu, Dongmei Wang

Erschienen in: European Journal of Drug Metabolism and Pharmacokinetics | Ausgabe 1/2018

Einloggen, um Zugang zu erhalten

Abstract

Background and Objectives

Pristimerin has been reported to possess a wide range of pharmacological activities. This study investigates the effects of glycyrrhizic acid on the pharmacokinetics of pristimerin in rats.

Methods

The pharmacokinetics of orally administered pristimerin (2 mg/kg) with or without glycyrrhizic acid pretreatment (at a dose of 100 mg/kg/day for 7 days) were investigated. The plasma concentration of pristimerin was determined using a sensitive and reliable LC–MS/MS method, and the pharmacokinetics profiles were calculated and compared. Additionally, Caco-2 cell transwell model and rat liver microsome incubation experiments were also conducted to investigate its potential mechanism.

Results

The results showed that when the rats were pretreated with glycyrrhizic acid, the maximum concentration (C _max) of pristimerin decreased from 186.43 ± 14.18 to 124.62 ± 18.49 ng/mL, and area under the concentration–time curve from zero to infinity (AUC_0–inf) also decreased from 918.54 ± 144.72 to 504.72 ± 115.63 μg·h/L. The elimination half-life (t _1/2) value of pristimerin decreased from 3.16 ± 1.18 to 1.88 ± 0.76 h (P < 0.05). The Caco-2 cell transwell experiments indicated that glycyrrhizic acid could increase the efflux ratio of pristimerin from 2.39 to 3.64, and the rat liver microsome incubation experiments showed that glycyrrhizic acid could significantly increase its intrinsic clearance rate from 51.87 ± 5.34 to 76.79 ± 8.52 µL/min/mg protein.

Conclusions

In conclusion, these results indicated that glycyrrhizic acid could affect the pharmacokinetics of pristimerin, and it might work through decreasing the absorption of pristimerin by inducing the activity of P-gp or through increasing the clearance rate in rat liver by inducing the activity of cytochrome P450 enzyme.

Tong L, Nanjundaiah SM, Venkatesha SH, Astry B, Yu H, Moudgil KD. Pristimerin, a naturally occurring triterpenoid, protects against autoimmune arthritis by modulating the cellular and soluble immune mediators of inflammation and tissue damage. Clin Immunol. 2014;155(2):220–30. doi:10.1016/j.clim.2014.09.014.CrossRefPubMed

Dos Santos VA, Dos Santos DP, Castro-Gamboa I, Zanoni MV, Furlan M. Evaluation of antioxidant capacity and synergistic associations of quinonemethide triterpenes and phenolic substances from Maytenus ilicifolia (Celastraceae). Molecules. 2010;15(10):6956–73. doi:10.3390/molecules15106956.PubMed

Costa PM, Ferreira PM, Bolzani Vda S, Furlan M, de Freitas Formenton Macedo Dos Santos VA, Corsino J, et al. Antiproliferative activity of pristimerin isolated from Maytenus ilicifolia (Celastraceae) in human HL-60 cells. Toxicol In Vitro 2008;22(4):854–863. doi:10.1016/j.tiv.2008.01.003

Deeb D, Gao X, Liu YB, Pindolia K, Gautam SC. Pristimerin, a quinonemethide triterpenoid, induces apoptosis in pancreatic cancer cells through the inhibition of pro-survival Akt/NF-kappaB/mTOR signaling proteins and anti-apoptotic Bcl-2. Int J Oncol. 2014;44(5):1707–15. doi:10.3892/ijo.2014.2325.CrossRefPubMedPubMedCentral

Eum DY, Byun JY, Yoon CH, Seo WD, Park KH, Lee JH, et al. Triterpenoid pristimerin synergizes with taxol to induce cervical cancer cell death through reactive oxygen species-mediated mitochondrial dysfunction. Anticancer Drugs. 2011;22(8):763–73. doi:10.1097/CAD.0b013e328347181a.CrossRefPubMed

Yang H, Landis-Piwowar KR, Lu D, Yuan P, Li L, Reddy GP, et al. Pristimerin induces apoptosis by targeting the proteasome in prostate cancer cells. J Cell Biochem. 2008;103(1):234–44. doi:10.1002/jcb.21399.CrossRefPubMed

Akao T, Hayashi T, Kobashi K, Kanaoka M, Kato H, Kobayashi M, et al. Intestinal bacterial hydrolysis is indispensable to absorption of 18 beta-glycyrrhetic acid after oral administration of glycyrrhizin in rats. J Pharm Pharmacol. 1994;46(2):135–7. doi:10.1111/j.2042-7158.1994.tb03756.x.CrossRefPubMed

Asl MN, Hosseinzadeh H. Review of pharmacological effects of Glycyrrhiza sp. and its bioactive compounds. Phytother Res. 2008;22(6):709–24. doi:10.1002/ptr.2362.CrossRefPubMed

Bhattacharjee A, Majumder S, Majumdar SB, Choudhuri SK, Roy S, Majumdar S. Co-administration of glycyrrhizic acid with the antileishmanial drug sodium antimony gluconate (SAG) cures SAG-resistant visceral leishmaniasis. Int J Antimicrob Agents. 2015;45(3):268–77. doi:10.1016/j.ijantimicag.2014.10.023.CrossRefPubMed

10.

Chen L, Yang J, Davey AK, Chen YX, Wang JP, Liu XQ. Effects of diammonium glycyrrhizinate on the pharmacokinetics of aconitine in rats and the potential mechanism. Xenobiotica. 2009;39(12):955–63. doi:10.3109/00498250903271997.CrossRefPubMed

11.

Sun Y, Song M, Niu L, Bai X, Sun N, Zhao X, et al. Antiviral effects of the constituents derived from Chinese herb medicines on infectious bursal disease virus. Pharm Biol. 2013;51(9):1137–43. doi:10.3109/13880209.2013.781197.CrossRefPubMed

12.

Tang Y, Zheng M, Chen YL, Chen J, He Y. Pharmacokinetic effects of cinnamic acid, amygdalin, glycyrrhizic acid and liquiritin on ephedra alkaloids in rats. Eur J Drug Metab Pharmacokinet. 2016;42(3):527–35. doi:10.1007/s13318-016-0368-8.CrossRef

13.

Chen Y, Wang J, Wang L, Chen L, Wu Q. Absorption and interaction of the main constituents from the traditional Chinese drug pair Shaoyao-Gancao via a Caco-2 cell monolayer model. Molecules. 2012;17(12):14908–17. doi:10.3390/molecules171214908.CrossRefPubMed

14.

Feng X, Ding L, Qiu F. Potential drug interactions associated with glycyrrhizin and glycyrrhetinic acid. Drug Metab Rev. 2015;47(2):229–38. doi:10.3109/03602532.2015.1029634.CrossRefPubMed

15.

Hu Q, Ding J, Liu S, Li P, Hu G. Pharmacokinetics of magnesium glycyrrhizinate following intravenous administration of magnesium glycyrrhizinate in rats. Eur J Drug Metab Pharmacokinet. 2003;28(4):259–64.CrossRefPubMed

16.

Liu Q, Jiao Z, Zhong M, Zhang M, Geng F, Zhao H. Effect of long-term coadministration of compound glycyrrhizin tablets on the pharmacokinetics of mycophenolic acid in rats. Xenobiotica. 2015;. doi:10.3109/00498254.2015.1103386.

17.

Tai T, Huang X, Su Y, Ji J, Jiang Z, Zhang L. Glycyrrhizin accelerates the metabolism of triptolide through induction of CYP3A in rats. J Ethnopharmacol. 2014;152(2):358–63. doi:10.1016/j.jep.2014.01.026.CrossRefPubMed

18.

Guo Y, Zhang W, Yan YY, Ma CG, Wang X, Wang C, et al. Triterpenoid pristimerin induced HepG2 cells apoptosis through ROS-mediated mitochondrial dysfunction. J BUON. 2013;18(2):477–85.PubMed

19.

Liu L, Li C, Yang P, Zhu J, Gan D, Bu L, et al. Association between alendronate and atypical femur fractures: a meta-analysis. Endocr Connect. 2015;4(1):58–64. doi:10.1530/ec-14-0120.CrossRefPubMedPubMedCentral

20.

Wang X, Zhang X, Huang X, Li Y, Wu M, Liu J. The drug–drug interaction of sorafenib mediated by P-glycoprotein and CYP3A4. Xenobiotica. 2015;46(7):651–8. doi:10.3109/00498254.2015.1109160.CrossRef

21.

Gao X, Zhang Y, Wang Y, Liu S. Influence of verapamil on pharmacokinetics of pristimerin in rats. Biomed Chromatogr. 2015;30(6):802–9. doi:10.1002/bmc.3611.CrossRefPubMed

22.

Hou YC, Lin SP, Chao PD. Liquorice reduced cyclosporine bioavailability by activating P-glycoprotein and CYP 3A. Food Chem. 2012;135(4):2307–12. doi:10.1016/j.foodchem.2012.07.061.CrossRefPubMed

23.

Yan G, Zhang H, Wang W, Li Y, Mao C, Fang M, et al. Investigation of the influence of glycyrrhizin on the pharmacokinetics of celastrol in rats using LC-MS and its potential mechanism. Xenobiotica. 2016;47(7):607–13. doi:10.1080/00498254.2016.1211773.CrossRefPubMed

Titel: Effects of Glycyrrhizic Acid on the Pharmacokinetics of Pristimerin in Rats and its Potential Mechanism
verfasst von: Xiufen Zhao
Yan Wu
Dongmei Wang
Publikationsdatum: 01.02.2018
Verlag: Springer International Publishing
Erschienen in: European Journal of Drug Metabolism and Pharmacokinetics / Ausgabe 1/2018
Print ISSN: 0378-7966
Elektronische ISSN: 2107-0180
DOI: https://doi.org/10.1007/s13318-017-0423-0

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Effects of Glycyrrhizic Acid on the Pharmacokinetics of Pristimerin in Rats and its Potential Mechanism

Abstract

Background and Objectives

Methods

Results

Conclusions

Die Highlights vom Kongress des American College of Cardiology 2024

Springer Medizin

Abstract

Background and Objectives

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 1/2018

Absorption, Distribution, Metabolism, and Excretion of [14C]-Volixibat in Healthy Men: Phase 1 Open-Label Study

Population Pharmacokinetic Analyses of Lithium: A Systematic Review

Population Pharmacokinetic Analysis of Bisoprolol in Patients with Stable Coronary Artery Disease

Effects of Metformin and Furosemide on Rosuvastatin Pharmacokinetics in Healthy Volunteers: Implications for Their Use as Probe Drugs in a Transporter Cocktail

Potential Influence of Endothelial Adsorption on the Delayed Time to Maximum Concentration of Biopharmaceuticals

Population Pharmacokinetic Modeling of Diltiazem in Chinese Renal Transplant Recipients